title: [Etretinate therapy in solitary keratoacanthomas].
abstract: In an open clinical trial, 5 patients suffering from solitary centrofacial keratoacanthoma were treated with etretinate. The dosage was 1,5 mg/kg body-weight. All patients showed complete healing after 4-5 weeks of therapy. There were no recurrences within 3 months after therapy.
authors.affiliation: Universitäts-Hautklinik Hamburg Eppendorf.
authors.forename: H
authors.initials: H
authors.lastname: Mensing
authors.forename: G
authors.initials: G
authors.lastname: Wagner
mesh_terms: D000284:Administration, Oral; D000368:Aged; D004305:Dose-Response Relationship, Drug; D005050:Etretinate / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009668:Nose Diseases / Q000188:drug therapy*; D012871:Skin Diseases / Q000188:drug therapy*
chemical_list: D005050:Etretinate
vernacular_title: Etretinat-Therapie bei solitären Keratoakanthomen.